Oxidative Damage Fine‐Tunes G‐Quadruplex Structures in Human Gene Promoters
Abstract
ABSTRACT Oxidative damage can convert guanine (G) into 8‐oxoguanine ( O8 G), resulting in altered gene expression and genome instability. However, the underlying molecular mechanisms remain poorly understood. Herein, we show that the NEIL3 gene proximal promoter sequence forms a mixture of parallel and hybrid G‐quadruplex structures ( NEIL3 ‐G4s), exhibiting intrinsic structural polymorphism. Strikingly, site‐specific O8 G modifications significantly reduce this polymorphism, promoting the stabilization of either the parallel or the (3+1) hybrid‐1 G4 topology. A single G‐to‐ O8 G substitution is sufficient to trigger a clear structural transition from the parallel to the (3+1) hybrid‐1 G4, highlighting the profound impact of O8 G on G4‐mediated epigenetic regulation. We have determined the NMR solution structures of both native and O8 G‐modified NEIL3 ‐G4s, providing mechanistic insights into how O8 G induces specific G4 structural rearrangements. Functional analysis demonstrates that both forms of NEIL3 ‐G4s can form in extended DNA contexts and inhibit DNA polymerase activity. Under oxidative stress, the formation of NEIL3 ‐G4s correlates with elevated NEIL3 gene expression, suggesting that they play a role as sensors of oxidative damage and function as molecular switches for gene upregulation. Collectively, these findings underscore the crucial role of O8 G‐induced G4 structural plasticity in the cellular response to oxidative stress and in regulating gene expression.
Article Details
Authors (11)
Yu Wang
Yingying Wang
Department of Psychology and Behavioral Sciences, Zhejiang University
Rongshuang Cheng
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing China
Xinyuan Chen
Zhiyu Tang
Xiaozhe Wang
State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China
Yushuang Liu
State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China
Shuo‐Bin Chen
Guangdong Provincial Key Laboratory of New Drug Design and Evaluation School of Pharmaceutical Sciences Sun Yat‐Sen University Guangzhou China
Shengtao Xu
State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University
Ling‐Yi Kong
State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China
Kai‐Bo Wang
State Key Laboratory of Natural Medicines Basic Medical Research Innovation Center for Anti‐Cancer Drugs (Ministry of Education of China) and Jiangsu Key Laboratory of Bioactive Natural Product Research China Pharmaceutical University Nanjing People's Republic of China